CEO SUMMARY: Having opened its CLIA-licensed laboratory in Huntington Beach, California, Agendia, Inc., becomes the newest competitor to enter the market for breast cancer testing. Its proprietary assay looks at 70 genes to assess the risk of recurrence. The company expects to collaborate with local pathologists, as its test requires fresh tissue and can provide
Tag: breast cancer test
CEO SUMMARY: In Canada, the story about inaccurate breast cancer testing just won’t go away. In March, the Cameron Report was made public with its assessment of lab testing failures in Newfoundland and Labrador. In April, the health system in those provinces admitted that it needed to review and possibly retest another 43 breast cancer
CEO SUMMARY: Facing a crisis due to several highly publicized deficiencies in lab testing, pathologists in Canada are using proficiency testing (PT) to improve standards. In British Columbia, PT is mandatory and every lab is evaluated every quarter. Pathologists in BC recommend that every province and territory adopt mandatory proficiency testing. Currently only British Columbia
CEO SUMMARY: Experts point out that widely publicized episodes of lab testing deficiencies in several provinces are signs that chronic underfunding of lab testing services is a key factor in these failures. To restore public confidence in breast cancer testing, the Canadian Association of Pathologists is developing a voluntary proficiency testing system for hospital labs
THIS ISSUE OF THE DARK REPORT YOU NOW HOLD IN YOUR HANDS demonstrates the perfect intersection of two trends. One trend, transparency in health outcomes and a public expectation of reduced medical errors, is a direct threat to laboratories which fail to deliver high-quality and accurate lab test results. The other trend is the way
GI Pathology, PLLC, of Memphis, Tennessee, announced that it has contracted to be a national gastrointestinal (GI) pathology laboratory provider with CIGNA HealthCare of Hartford, Connecticut. It also has a five year, national provider contract with UnitedHeathCare.
SPENDING CUTS ADVERSELY AFFECT CANADIAN LABS
Widely-publicized errors in pathology services have caught the attention of the Canadian public. Pathologist
CEO SUMMARY: Recent developments in breast cancer testing are leading to changes in pathology. Oncologists and pathologists have issued new guidelines regarding HER2 testing and new research suggests changes may be coming for estrogen-receptor testing as well. For the first time, the new guidelines require a certain level of testing and new procedures for pre-analytical
Last Friday, Luminex Corporation of Austin, Texas announced that it would acquire Tm Bioscience Corp. of Toronto, Ontario. Luminex will pay $44 million, which represents a 41.5% premium for Tm shares based on the December 14 closing price. Tm Bioscience has tests for DNA-based diagnostics, including tests for infectious diseases and genetic mutations related to
CEO SUMMARY: Every second year, THE DARK REPORT releases its list of key trends in anatomic pathology. These trends help shape an understanding about the state of the pathology profession. Our current list includes 11 identifiable trends. This is not an auspicious sign for pathologists who prefer things to remain the same. Eleven distinct trends
PREDICTIVE TESTING FOR RECURRENT BREAST CANCER
LABORATORY TESTS DESIGNED to predict the recurrence of breast cancer are picking up momentum. First to market was Genomic Health Inc.’s Oncotype DX™ breast cancer test. Now TriPath Imaging, Inc. is reporting favorable results from studies of its ProEx Br markers for breast cancer.
Since introducing Oncotype DX in 2004, Genomic